• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
76,672.73 1,144.78
( 1.52%)
Global Indices
Nasdaq
51,233.54 363.79
(0.72%)
Dow Jones
7,453.14 37.84
(0.51%)
Hang Seng
66,063.56 1,846.29
(2.88%)
Nikkei 225
10,460.24 156.36
(1.52%)
Forex
USD-INR
95.49 0.16
(0.17%)
EUR-INR
110.25 0.17
(0.15%)
GBP-INR
127.74 0.15
(0.12%)
JPY-INR
0.60 0.00
(0.21%)

EQUITY - MARKET SCREENER

Glenmark Pharmaceuticals Ltd
Industry :  Pharmaceuticals - Indian - Bulk Drugs & Formln
BSE Code
ISIN Demat
Book Value()
532296
INE935A01035
855.7849313
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
GLENMARK
38.33
61327.88
EPS(TTM)
Face Value()
Div & Yield %
56.7
1
0.12
 

ceat ltd
Board of Canara Bank approves capital raising up to Rs 8,500 cr for FY 2027
Jun 02,2026

The board of Canara Bank in its meeting held today on 02 June 2026 has approved the Capital Raising Plan of the Bank for the financial year 2026-27 amounting upto Rs.8,500 crore by way of Debt Instruments (Additional Tier I/Tier II Bonds).

Further, out of the above Capital Raising Plan, the Board of Directors of the Bank has approved the following:

  • To raise Capital through Basel III Compliant Additional Tier I Bonds to the extent of Rs.4,500 crore during the FY 2026-27, subject to market conditions and necessary approvals.
  • To raise Capital through Basel III Compliant Tier II Bonds to the extent of Rs.4,000 crore during the FY 2026-27, subject to market conditions and necessary approvals.